A Clinical Study on Hemodynamic Changes by the Low Dose of Tolvaptan in Heart Failure Patients

A Clinical Study on Hemodynamic Changes by the Low Dose of Tolvaptan in Heart Failure Patients - A Study on Hemodynamic Changes by the Low Dose of Tolvaptan

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008028

Enrollment

Registered

2012-06-01

Start date

2012-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Interventions

Tolvaptan is administered from the dose of 3.75mg/day. The dose of tolvaptan can be stepwise increased to 7.5mg/day, then 15mg/day.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients with heart failure of Nohria/Steavenson B & C who need Swan-Ganz catheter for hemodynamic monitoring.

Exclusion criteria

Exclusion criteria: 1) the patient's s-Na >147mEq/L at the administration of tolvaptan 2) the patients showing shock 3) the patient's creatinine >3.0mg/dL 4) the patient showing allergy to tolvaptan 5) pregnant patient 6) the patient regarded as inappropriate for this clinical study by the principal investigator

Design outcomes

Primary

Measure	Time frame
Hemodynamic Changes, Change of Body Weight	—

Countries

Japan

Contacts

Public ContactShinichi Nunoda. M.D., Ph.D.

Tokyo Women's Medical University Medical Center East Cardiovascular Division

nunodagm@dnh.twmu.ac.jp03-3810-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026